Esperite ESP with The Cell Factory prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn's Bronchopulmonary dysplasia Epilepsy and Stroke Amsterdam The Netherlands 29 November 2018 The Cell F...